Showing results (21-30 of 204) with videos related to

Sort By:
Pageof 21
CEN Case Reports|February 13, 2026
Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two CasesSiarhei Dzedzik, Ilya Glezerman, Andrew D Zelenetz, et al.
Leukemia & Lymphoma|February 2, 2013
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphomaCarla Casulo, Heiko Schöder, John Feeney, et al.
British Journal of Haematology|October 13, 2015
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab eraAnita Kumar, Matthew A Lunning, Zhigang Zhang, et al.
American Journal of Hematology|August 28, 2022
A roadmap for clinical trial design in marginal zone lymphomaJuan Pablo Alderuccio, Thomas Habermann, Russ Kuker, et al.
Clinical Advances in Hematology & Oncology : H&O|June 24, 2008
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphomaJohn P Leonard, Stephanie A Gregory, David G Maloney, et al.
Leukemia & Lymphoma|July 12, 2003
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expressionEunice S Wang, Owen O'Connor, Yuhong She, et al.
Leukemia & Lymphoma|February 3, 2022
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphomaThaís Fischer, Andy Ni, Kurt S Bantilan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
NCCN Roundtable: What Are the Characteristics of an Optimal Clinical Practice Guideline?David S Ettinger, Michael Kuettel, Jennifer Malin, et al.
Blood|August 25, 2010
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Joachim Yahalom, Tarun Kewalramani, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 15, 2018
Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With RituximabEri Matsuki, Olga L Bohn, Siraj El Jamal, et al.
Pageof 21